share_log

花旗:予华润医疗(01515)“买入”评级 目标价7港元

Citigroup: rated cr medical(01515) as "buy" with target price of HKD 7.

Zhitong Finance ·  Jul 26 11:51

Citigroup expects that the stock price of CR Medical (01515) will have a negative reaction to its performance pressure.

According to the Zhixin Finance app, Citigroup released a research report stating that it rates CR Medical (01515) as 'buy' and expects that the stock price will have a negative reaction to its performance pressure, with a target price of HK$7. The bank is observing a 30-day downward catalyst and expects the company's first-half performance to disappoint the market, primarily due to potential devaluation of Huaiyin Hospital and slow revenue growth of CR Health (Liaoning) compared to expectations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment